

## India 2021 Outlook

# Vaccine To Extend Rebound in FY22

We expect that the broad-based availability of an effective vaccine in India could allow containment policies and mobility to normalize by mid-2022. This should allow a meaningful activity rebound in 2021 – particularly in consumer-facing services sectors, where activity remains significantly below pre-COVID levels.

The pace of the rebound will be restrained by some economic scarring and a number of factors including a weak labor market, the hit to private sector incomes and balance sheets, tighter credit supply conditions and a limited impetus from fiscal policy. Overall, we expect real GDP growth to rebound to 13% in FY22 (above consensus expectations of 10.9%), after an expected -10.3% contraction in FY21.

We expect headline inflation to decline towards the mid-point of the RBI's target band of 2%-6% by mid-2021 as food prices fall on easing supply restrictions, a benign monsoon, and favorable base effects. Core inflation could also moderate given low manufacturing capacity utilization and INR appreciation.

Easing inflationary pressures should create more room for RBI easing. The composition of the MPC committee has moved in a more dovish direction in recent months, and strengthened forward guidance introduced in October suggests that members are awaiting an easing in inflation to use available room to support the economy further. We expect RBI to cut policy rates by another 35bp early next year.

**Jonathan Sequeira**  
+65-6889-2472 |  
jonathan.sequeira@gs.com  
Goldman Sachs (Singapore) Pte

**Andrew Tilton**  
+852-2978-1802 | andrew.tilton@gs.com  
Goldman Sachs (Asia) L.L.C.

## Broad-Based Vaccine Availability To Catalyze Growth Rebound in FY22

Exhibit 1: Our main FY21 forecasts

	FY19 <sup>^</sup>	FY20	FY21F		FY22F	
	Actual	Actual	GS	Consensus	GS	Consensus
Real GDP (YoY%)	6.1	4.2	-10.3	-9.7	13	10.9
CPI inflation (YoY%)	3.4	4.8	6.2	5.5	4.6	4.4
Current account (% of GDP)	-1.8	-2.1	2.3	0.9	0.3	-0.8
Repo Rate (% , EOP)	6.25	4.40	3.65	3.90	3.65	3.70
FX (USD/INR, EOP)	69.2	75.4	72	74	70	72.55

<sup>^</sup>FY19 refers to April 2018 to March 2019

Source: Bloomberg, Consensus Economics, Goldman Sachs Global Investment Research

**In India new coronavirus cases peaked at around 90,000/day in September, and have since fallen to ~50,000/day in the past few weeks.** The positive testing rate has also declined slightly – to 7.1% last week, from a peak of 8.5% in September – with the country still testing ~1.1 million samples per day. These are somewhat encouraging trends for an economy that has struggled with virus containment this year.

**However, it is still too early to call time on the virus.** Indications are that usage of precautionary measures such as prudent distancing and mask use have fallen meaningfully as virus numbers eased. Social interactions also increased in the run-up to the Deepavali holiday on 14 November, with the ongoing wedding season and onset of colder temperatures in northern India also creating upside risks to the recent virus trajectory. Given these risks, we remain conservative on our assumptions for containment policy and mobility through early 2021.

Beyond that, however, **a pivotal assumption for our 2021 India growth outlook is broad-based availability of an effective vaccine, which could allow containment policies and mobility to normalize fully by mid-2022.** The [national implementation plan on vaccine disbursement](#) – which is currently in its draft stages – aims to immunize around 23% of the population (or ~300mn people) in the first phase [by mid-2021](#) ([Exhibit 2](#)). The immunization will start with front-line healthcare workers, public service professionals like the police, municipal workers, teachers, transport workers and cleaners, those aged 50 years and above, and those with co-morbidity conditions.

**On our India healthcare team's estimates, indigenous vaccine production capacity could reach 0.9bn doses next year** – which could inoculate up to 450mn high-risk individuals by end-2021 ([Exhibit 3](#)). India's indigenous vaccine production capabilities, and administrative experience with large-scale public vaccination campaigns such as polio, could also lead to quicker disbursement of the vaccine when available.

**Exhibit 2: National vaccination strategy aims to immunize 300mn high-risk individuals by mid-2021...**

Priority groups for Phase 1 vaccination	Numbers mn	% total population
Healthcare Workers	5	0.4
Frontline Workers	20	1.5
Municipal Workers	15	1.2
People > 50 years / < 50 years with co-morbidities	260	19.9
<b>Phase 1 Total</b>	<b>300</b>	<b>23.0</b>

Source: The Times of India

**Exhibit 3: ...with indigenous vaccine production capacity potentially reaching 0.9bn doses by end-2021**

Producer	Vaccine name	Partner	Clinical phase*	Expected dose 2021 (mn)
Bharat Biotech	COVAXIN	ICMR/ NIV	Phase 3/3	300
Serum Institute	Covishield	Astra Zeneca	Phase 2/3	300
Zydus Cadila	ZyCoV-D	--	Phase 2/3	100
Dr Reddy's	Sputnik V	RDIF	Pending trials	100
Serum Institute	NVX-CoV2373	Novavax	Pending trials	50


\*Clinical phase refers to vaccine current clinical phase in India

Source: Indian Express, ICMR, Economic Times

**Broad-based vaccine deployment should allow a meaningful activity rebound in FY22, particularly in the services sector.** For now – given the risks around vaccine availability and disbursement – we make the assumption that broad-based vaccine deployment will allow full containment policy/mobility normalization – as captured by our GS effective lockdown index (ELI) – by mid-2022. This should allow a meaningful activity rebound in FY22 (which runs from April 2021 to March 2022) – particularly in the services sector, where activity levels are still significantly below pre-COVID levels (Exhibit 4).

**We expect GDP growth to rebound to 13% in FY22 (above consensus expectations of 10.9%), after an expected 10.3% contraction in FY21.** There is still a high degree of uncertainty around the outlook – and growth could significantly overshoot or undershoot these forecasts – depending on the course taken by the virus and vaccine-related developments in the coming year. Exhibit 5 for instance, plots alternative growth scenarios from our ELI based regional growth model, which assumes that the ELI could either normalize two quarters earlier (“bullish”), or remain significantly tighter through mid-2021, and then normalize at a much slower pace (“bearish”) relative to our baseline that ELI normalizes fully by mid-2022.


**Exhibit 4: Services sector indicators still significantly below pre-virus levels**



**Industry indicator** is simple average of Electricity consumption, E-way bills, Cement and Steel production. **Services indicator** is simple average of railway freight and passenger services, air passenger and cargo services, port volume and motor vehicle registrations.

Source: Goldman Sachs Global Investment Research, CEIC

**Exhibit 5: Growth outcomes highly dependent on virus path and containment policy**




Source: Goldman Sachs Global Investment Research, University of Oxford (covidtracker.bsg.ox.ac.uk), Google LLC “Google COVID-19 Community Mobility Reports”, Accessed: 2020-11-10.

The pace of the rebound, however, will be restrained by some economic scarring

caused by a number of factors:


- Weak labor market likely to weigh on pace of consumption rebound.** While the unemployment rate is already back to pre-COVID levels, the labor force participation rate is still 2pp below pre-COVID levels (Exhibit 6). On top of that, new jobs created have anecdotally been at lower wages or in lower income brackets, which is borne out by data on the composition of jobless individuals which suggests that the job recovery has been slowest for salaried employees (Exhibit 7). This coupled with weak fundamentals even prior to COVID-19 (the labor force participation rate has fallen, and unemployment rate has risen significantly since 2017), declining consumer confidence, household debt overhang and NBFC credit crunch – are likely to weigh on the pace of consumption rebound going forward.

**Exhibit 6: Unemployment has normalized, but participation rate still 2pp below pre-COVID levels**



Source: CMIE

**Exhibit 7: Job recovery for salaried employees has been slowest**




Source: CMIE

- Hit to corporate balance sheets, low manufacturing capacity utilization to drag on private investment rebound.** A sharp rise in the corporate interest burden on the earnings contraction this year (Exhibit 8) and consequent implied decline in debt servicing capability, potential tightening in credit supply<sup>1</sup> on higher bank credit costs<sup>2</sup> (Exhibit 9), low manufacturing capacity utilization, the inventory overhang in residential housing along with entrenched business pessimism are likely to drag on the private investment rebound going forward.

<sup>1</sup> We did a deep dive on how increases in non-performing loans and bank credit costs in India impact bank credit supply and investment growth in “Still no ‘bank’ing on growth”, Asia Economics Analyst, 28 September, 2017.


<sup>2</sup> The credit cost increase has been contained so far as measures by policymakers including the extension of debt moratoriums on repayment, debt restructuring, and temporary suspension of the Insolvency and Bankruptcy Code have helped ease the repayment pressure faced by corporates.

**Exhibit 8: Sharp increase in corporate interest burden**



Source: Reserve Bank of India, CEIC, Goldman Sachs Global Investment Research


**Exhibit 9: Banks' credit costs to rise on NPL increase**



Source: Goldman Sachs Global Investment Research

- **Appetite to dial up fiscal stimulus further appears to be quite muted.** The total discretionary component of the fiscal stimulus this year has been just over 2.5pp of 2019 GDP, which is small relative to the magnitude of the economic shock and potential for cascading income impacts due to the hit to households' and firms' earnings this year. In FY22, we expect the fiscal deficit to narrow to 6.5% of GDP, from a forecasted 8% of GDP in FY21 (versus 4.6% of GDP in FY20). We expect the general government deficit (center + states) to narrow to 9.5% of GDP in FY22, from a forecasted 11.5% of GDP in FY21 (versus 7.2% in FY20). This suggests that the total fiscal policy contribution to growth will decline further in FY22 (Exhibit 10).
- However, even after building in relatively significant assumptions for economic scarring we still have GDP growth rebounding 13% in FY22, with some upside to consensus growth expectations of a 10.9% GDP growth rebound in FY22.


**Exhibit 10: Fiscal policy will turn to a growth drag in FY22**



\* GS estimate; ^Aggregate contribution of centre and state governments

Source: Haver Analytics, CEIC, Goldman Sachs Global Investment Research

**Exhibit 11: Resurgent rural demand one of only few bright spots in economy this year**



Source: CEIC, Labour bureau

One of the only **bright spots this year has been rural demand** (Exhibit 11), which was relatively less impacted by COVID-related restrictions and boosted by supportive government policy in the first half of the fiscal year. The favorable terms of trade and good monsoon planting trends continue to bode well for rural demand although somewhat lower policy support in 2H FY21 and a potential swing in the terms of trade as food prices decline could moderate the pace of rural growth going forward.

In addition, **some meaningful positive medium-term catalysts emerged this year**, with momentum building behind the “Make in India” campaign with a total of US\$30bn of production-linked incentives for certain industries, autos in particular, announced earlier this week. The “Make in India” self-reliance initiative will use import disincentives, production-linked incentives, tax benefits and digitization in an attempt to increase the share of manufacturing in India’s GDP from 17% now to 25% in the medium term, while creating 100mn new jobs. There was also significant progress on the structural reform agenda with the administration passing three new labor bills (which make it much easier to start and scale up businesses while engendering greater formalization of the labor force – 85% of which is estimated to still be in the informal sector) and three new farm bills (which deregulate stocking of key food commodities, create more competition in wholesale food markets by allowing farmers to sell their produce to any buyer in the country, and allow contract farming).

**The administration appears set to continue reform momentum**, with the Minister of State for Commerce and Industry recently stating that the government is in the final stages of drafting a national logistics policy, new industrial policy, E-commerce policy and national retail trade policy.

## **Easing Mobility Constraints, Good Monsoon to Push Headline Inflation Back into Target Band**

A key constraint on the monetary policy response this year has been inflation, which has persisted above the target band since December last year. The key drivers of elevated inflation this year have been food, excise tax hikes on petrol/diesel/tobacco, and gold prices. Excluding these components (which constitute about half of the CPI basket) from the CPI calculation, suggests underlying inflation has been tracking at just 4.3% on average over the past 3 months, and 4.0% on average since January.

Going forward, we expect **food prices to fall on the back of the abundant monsoon,<sup>3</sup> continued compression of retail margins as mobility constraints ease, and favorable base effects** (Exhibit 12). Transport and communication inflation is also projected to decline<sup>4</sup>, although fuel inflation (mainly electricity, LPG and Kerosene) will likely pick up on higher global energy prices. Core inflation<sup>5</sup> – which strips out a number of volatile factors like food (including tobacco/other intoxicants), transport and fuel prices – could also decline from here on low capacity utilization, INR appreciation, and a lower forecasted pace of increase in gold prices in 2021.


<sup>3</sup> Cumulative rainfall was 10% above long-term average, area sown under the summer kharif crop expanded by close to 5%, and advance kharif estimates suggest substantial increases in crop output and indications of a healthy harvest

<sup>4</sup> In 2020, in contrast to most other countries, retail fuel prices actually went up in India despite the fall in global energy prices, as the government refrained from lowering prices and hiked excise taxes significantly. So even though global energy prices are likely to rebound next year, we see limited domestic price increases and a decline in transportation inflation given the disappearance of large base effects from the excise tax hike earlier this year.

<sup>5</sup> On our estimates, around 70% of the core inflation increase this year was driven by the gold price spike, and is not a reflection of a generalization of recent elevated headline inflation prints into core inflation momentum. Recent RBI models – as highlighted by Dr Michael Patra in the recent MPC minutes – also suggest that 71% of the recent deviation of inflation from target was due to supply shocks from food and fuel prices, with only 4% of the deviation on account of money supply/easier monetary policy.


Overall, pulling all these drivers together, we expect **headline inflation** – which rose to 7.6% yoy in October – **to decline back into the RBI's target band of 2%-6% in coming months** (Exhibit 13). We think inflation could be back at the midpoint of the target band by mid-2021 on the back of lower food, transportation and core inflation. The key risks to our view are that food inflation momentum remains high in coming months, and that recent headline inflation prints and high inflation expectations begin to generalize into higher core inflationary pressures dragging inflation higher despite subdued demand pressures.

**Exhibit 12: Retail margins could continue to compress as mobility constraints ease**



Source: Goldman Sachs Global Investment Research, Haver Analytics, Google COVID-19 Community Mobility Reports, Accessed: 2020-11-10.

**Exhibit 13: Headline inflation to fall back within RBI's inflation target band in coming months**



Source: Haver Analytics, RBI, Goldman Sachs Global Investment Research

## RBI to Ease Modestly as Inflation Falls Back Within Comfort Zone

Since the beginning of the year, the RBI has used three instruments – policy rates, forward guidance and liquidity – to maintain accommodative policy. While persistent inflation pressures prevented the MPC from cutting policy rates beyond the 115bp through May, strengthened forward guidance kept a lid on rate increases, and banking system liquidity injections pushed effective rates down another 60bp to the bottom of the policy band.

Going forward, as activity stays weak, we forecast that RBI could cut policy rates another 35bp early next year as inflation falls back within the target band (Exhibit 14). In addition, the surge in the banking system surplus liquidity position on RBI injections could keep effective rates pinned to the bottom end of the policy band (Exhibit 15).


While there is significant uncertainty around the inflation path, we see another cut as still being more likely than not as recent leadership/compositional shifts in the MPC – including the recent addition of new external members – skews the reaction function in a more dovish direction by placing much higher emphasis on growth versus inflation. Muted appetite to stimulate on the fiscal front, as well as the RBI's strengthened forward guidance<sup>6</sup> at the October meeting also argue for modest easing should inflation

<sup>6</sup> MPC members resolving to keep the accommodative monetary policy stance "as long as necessary, at least through the current financial year and into the next year to revive growth". The Governor emphasized the "transient" inflation trend could be "looked through at this juncture while setting the stance of monetary policy", and that MPC would "await the easing of inflationary pressures to use the space available for

decline in coming months.


The key risk to our view is that inflation – particularly food prices – stays elevated or rises further from here over the next 2-3 months and/or if there are signs that elevated inflation prints this year are generalizing into higher core pressures via higher inflation expectations. If this transpires then further policy easing would likely be off the table next year, and RBI would have to re-think its stance on policy rates, forward guidance and liquidity.

**Exhibit 14: We expect RBI to cut policy rates again in early 2021**



Source: RBI, Goldman Sachs Global Investment Research

**Exhibit 15: Abundant RBI liquidity could keep effective rates pinned to bottom of policy band**



Source: Haver Analytics, Goldman Sachs Global Investment Research

The authors would like to thank Suraj Dhunna - an intern on the India Economics team - for his contributions to the report.

supporting growth further”



# Disclosure Appendix

## Reg AC

We, Jonathan Sequeira and Andrew Tilton, hereby certify that all of the views expressed in this report accurately reflect our personal views, which have not been influenced by considerations of the firm's business or client relationships.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

## Disclosures

### Regulatory disclosures

#### Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage.

**Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

#### Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of the Global Investment Research Division of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Brazil:** Disclosure information in relation to CVM Instruction 598 is available at <https://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Instruction 598, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** Goldman Sachs Canada Inc. is an affiliate of The Goldman Sachs Group Inc. and therefore is included in the company specific disclosures relating to Goldman Sachs (as defined above). Goldman Sachs Canada Inc. has approved of, and agreed to take responsibility for, this research report in Canada if and to the extent that Goldman Sachs Canada Inc. disseminates this research report to its clients. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 951-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

**European Union:** Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <https://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

**Japan:** Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan and Type II Financial Instruments Firms Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to

any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

## Global product; distributing entities

The Global Investment Research Division of Goldman Sachs produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Ombudsman Goldman Sachs Brasil: 0800 727 5764 and / or [ouvidoriagoldmansachs@gs.com](mailto:ouvidoriagoldmansachs@gs.com). Available Weekdays (except holidays), from 9am to 6pm. Ouvidoria Goldman Sachs Brasil: 0800 727 5764 e/ou [ouvidoriagoldmansachs@gs.com](mailto:ouvidoriagoldmansachs@gs.com). Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by either Goldman Sachs Canada Inc. or Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom and European Union.

**European Union:** Goldman Sachs International authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, has approved this research in connection with its distribution in the European Union and United Kingdom.

## General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by our Global Investment Research Division. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<https://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is focused on investment themes across markets, industries and sectors. It does not attempt to distinguish between the prospects or performance of, or provide analysis of, individual companies within any industry or sector we describe.

Any trading recommendation in this research relating to an equity or credit security or securities within an industry or sector is reflective of the investment theme being discussed and is not a recommendation of any such security in isolation.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <https://www.theocc.com/about/publications/character-risks.jsp> and

[https://www.fiadocumentation.org/fia/regulatory-disclosures\\_1/fia-uniform-futures-and-options-on-futures-risk-disclosures-booklet-pdf-version-2018](https://www.fiadocumentation.org/fia/regulatory-disclosures_1/fia-uniform-futures-and-options-on-futures-risk-disclosures-booklet-pdf-version-2018).

Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

**Differing Levels of Service provided by Global Investment Research:** The level and types of services provided to you by the Global Investment Research division of GS may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <https://research.gs.com>.

Disclosure information is also available at <https://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

© 2020 Goldman Sachs.

**No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written**

consent of The Goldman Sachs Group, Inc.